Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Smith

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 6, 2020
Comparison of 18FDG-PET/CT and conventional follow-up methods in colorectal cancer: A randomised prospective studyJacques Monteil, Valerie Le Brun-Ly, Florent Cachin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 3, 2020
Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)Louis de Mestier, Come Lepage, Eric Baudin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2023
Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trialDavid Malka, Benjamin Verret, Matthieu Faron, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2014
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised studyJean-Marc Phelip, Véronique Vendrely, Florian Rostain, et al.
Nature Medicine|March 17, 2026
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialKohei Shitara, Hirokazu Shoji, Nicola Fazio, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2022
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD studyCôme Lepage, Jean-Marc Phelip, Astrid Lievre, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2016
Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancerMohamed Bouchahda, Valérie Boige, Denis Smith, et al.
The Lancet. Oncology|February 5, 2023
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trialThomas Walter, Astrid Lievre, Romain Coriat, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|December 13, 2017
Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver MetastasesFrançois Tranquart, Paul-Armand Dujardin, Olivier Bouché, et al.
The New England Journal of Medicine|February 11, 2011
Sunitinib malate for the treatment of pancreatic neuroendocrine tumorsEric Raymond, Laetitia Dahan, Jean-Luc Raoul, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 6, 2020
Comparison of 18FDG-PET/CT and conventional follow-up methods in colorectal cancer: A randomised prospective studyJacques Monteil, Valerie Le Brun-Ly, Florent Cachin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 3, 2020
Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)Louis de Mestier, Come Lepage, Eric Baudin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2023
Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trialDavid Malka, Benjamin Verret, Matthieu Faron, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2014
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised studyJean-Marc Phelip, Véronique Vendrely, Florian Rostain, et al.
Nature Medicine|March 17, 2026
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialKohei Shitara, Hirokazu Shoji, Nicola Fazio, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2022
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD studyCôme Lepage, Jean-Marc Phelip, Astrid Lievre, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2016
Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancerMohamed Bouchahda, Valérie Boige, Denis Smith, et al.
The Lancet. Oncology|February 5, 2023
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trialThomas Walter, Astrid Lievre, Romain Coriat, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|December 13, 2017
Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver MetastasesFrançois Tranquart, Paul-Armand Dujardin, Olivier Bouché, et al.
The New England Journal of Medicine|February 11, 2011
Sunitinib malate for the treatment of pancreatic neuroendocrine tumorsEric Raymond, Laetitia Dahan, Jean-Luc Raoul, et al.
Pageof 10